Holen Sie sich die Stockscreener-App
5.42
11.00%
-0.67
Handel nachbörslich:
5.48
0.06
+1.11%
Schlusskurs vom Vortag:
$6.09
Offen:
$5.99
24-Stunden-Volumen:
228.47K
Relative Volume:
0.26
Marktkapitalisierung:
$5.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-8.3385
EPS:
-0.65
Netto-Cashflow:
$-13.75M
1W Leistung:
+32.20%
1M Leistung:
+19.09%
6M Leistung:
-25.24%
1J Leistung:
-43.51%
1-Tages-Spanne:
$5.31
$6.07
1-Wochen-Bereich:
$3.80
$7.50
52-Wochen-Spanne:
$3.61
$17.40
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(818) 422-6172
Adresse
2110 NARCISSUS CT, VENICE
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News
PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal
Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal
Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR
Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices
Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire
Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga
Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance
Why XPeng Stock Spiked Higher Today - Yahoo! Voices
Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL
KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News
Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga
English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices
Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch
Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices
Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph
Why Is Pasithea Therapeutics Stock Surging On Thursday? - Yahoo Finance
Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM
Pasithea reports positive early data on cancer drug PAS-004 - Investing.com
Pasithea Therapeutics : Investor Presentation - Marketscreener.com
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM
Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com
Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan
Factbox-OpenAI key personnel changes - Yahoo! Voices
Why Viking Therapeutics Stock Was So Healthy on Wednesday - Yahoo Finance
Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding - Marketscreener.com
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Capstan Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC - OncLive
The OncFive: Top Oncology Articles for the Week of 9/15 - OncLive
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - Yahoo Finance
Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock? - Yahoo Finance
Pasithea Therapeutics (NASDAQ:KTTA) Trading Up 25.8% - Defense World
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
KTTAPasithea Therapeutics Corp. Latest Stock News & Market Updates - StockTitan
Saghmos Therapeutics Announces Presentation at UBS 2024 Biotechnology Private Company Virtual Symposium - Yahoo Finance
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer - Yahoo Finance
Why Investors Plowed Into Viking Therapeutics Stock Today - Yahoo Finance
Pasithea reports positive results in PAS-004 toxicity studies - Investing.com
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - GlobeNewswire
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - StockTitan
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):